The effect of the current privatized model of pharmaceutical innovation on the development and affordability of lifesaving vaccines and medicines has been an enduring source of conflict. The need to promote and reward the development of new drugs and devices through patent protection—and the high prices this promotion and protection generate—seem to adversely affect equitable access to essential medicines and the right to health. Throughout the world, even in the United States, the high cost of pharmaceuticals provokes controversy, as is evident with the pricing of the epinephrine injection (EpiPen) and ledipasvir/sofosbuvir (Harvoni).
Burci GL, Gostin LO. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits. JAMA. 2017;317(5):473–474. doi:10.1001/jama.2016.17994
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: